

5 WHAT IS CLAIMED IS:

1. A method of identifying a secondary drug target comprising:
- (a) providing a cell having a genome, including at least one primary gene defect;
- (b) effecting one or more mutations in said genome of said cell, at one or
- 10 more secondary sites;
- (c) selecting at least one secondary site mutation that proves lethal to said cell; and
- SUB B1) (d) determining the gene product of said lethal secondary site to provide a secondary drug target.

15

2. The method of claim 1 in which said primary gene defect is found in or associated with a human tumor.

3. The method of claim 1 in which said primary gene defect is analogous or

20 homologous to a defect found in or associated with a human tumor.

4. The method of claim 1 in which said primary gene defect results in the alteration, loss, inhibition, enhancement, or gain of a function.

5. The method of claim 4 in which said function includes the suppression of tumor growth, DNA damage checkpoint, DNA mismatch repair, nucleotide excision repair, O6-methylguanine reversal, double-strand break repair, DNA helicase function, signaling, cell cycle control, or apoptosis.

25

6. The method of claim 5 in which said signaling function includes signal transduction, tissue growth factor signaling, autocrine loop signaling, or paracrine loop signaling.

30

5           7.       The method of claim 1 in which said primary gene defect includes a defect  
in the gene coding for p16, p53, ATM, MSH2, MLH1, XP-A, XP-B, MGMT, BRCA2,  
BRCA1, BLM, RAS, NF1, MYC, PTH, Cyclin D, Cyclin E, p27kip1, Rb, or BCL-2.

10           8.       The method of claim 1 in which said primary gene defect includes a defect  
in the gene coding for RAD9Sc, rad1+Sp, MEC1Sc, TEL1Sc, rad3+Sp, mei-41Dm,  
MSH2Sc, MLH1Sc, RAD14Sc, RAD25Sc, MGT1Sc, RAD51Sc, RAD54Sc, SGS1Sc,  
rqh1+Sp, dRASDm, RASCe, RAS1Sc, RAS2Sc, let-60Ce, IRA1Sc, IRA2Sc, dMycDm,  
patchedDm, CLN1Sc, CLN2Sc, Cyclin DDm, Cyclin EDm, SIC1Sc, RbfDm, or ced-9Ce.

15           9.       The method of Claim 1 in which said primary gene defect includes a  
defect in a gene coding for CLN2.

20           10.      The method of claim 1 in which said secondary site mutation is effected  
within a gene selected from the group consisting of cdc9, cdc2, a gene encoding a gene  
product exhibiting polymerase  $\delta$  exonuclease function, a gene encoding a gene product  
exhibiting polymerase  $\epsilon$  exonuclease function, a gene encoding a ribonucleotide  
reductase, mec1, rad53 like gene, cdc53, cdc34, cdc14, cdc15, a gene encoding NUP170,  
dbf2, a gene encoding CLN2, rad3, rad9, rad27, cdc8, a gene encoding Mlu1-box binding  
factor, slm1, a gene encoding MBF, a gene encoding PCNA, or a gene encoding a  
25           replication fork protein.

30           11.      The method of Claim 1 in which said secondary site mutation is effected  
within a gene coding for a gene product selected from PIK-related kinase (mec1), E2  
ubiquitin carrier protein (cdc34), E3 ubiquitin ligase (cdc53), ubiquitin ligase (skp1),  
protein phosphatase (cdc14) and nuclear pore protein (NUP170).

12.      The method of claim 1 in which said secondary site mutation is effected  
within a gene having a mammalian analog or homolog.

5           13.     The method of claim 12 in which said homologous mammalian gene is selected from the group consisting of a gene encoding a DNA ligase I, a gene encoding a DNA polymerase, a gene encoding a ribonucleotide reductase, a gene encoding a FEN-1, a gene encoding Cyclin D, a gene encoding Cyclin E, an AT-related gene, a gene encoding NUP155, or a gene encoding an isozyme.

10           14.     The method of Claim 1 in which said primary gene defect includes a defect in a gene coding for CLN2 and said secondary site mutation is effected within a gene coding for a gene product selected from PIK-related kinase (mec1), E2 ubiquitin carrier protein (cdc34), E3 ubiquitin ligase (cdc53), ubiquitin ligase (skp1), protein  
15     phosphatase (cdc14) and nuclear pore protein (NUP170).

          15.     The method of claim 1 which further comprises using said secondary drug target to screen for a drug or drug candidate.

20           16.     The method of claim 15 in which said drug or drug candidate interacts with, binds to, or inhibits a gene product selected from the group consisting of DNA ligase, DNA polymerase, polymerase  $\delta$  exonuclease, polymerase  $\epsilon$  exonuclease, ribonucleotide reductase, a subunit of transcriptional activator, a transcription factor, PCNA, a replication fork protein, PIK-related kinase, recombinase, E3 ubiquitin ligase,  
25     E2 ubiquitin carrier protein, a protein tyrosine phosphatase, a nuclear pore protein, cyclin, DNA repair exonuclease, thymidylate kinase, gene product of slm1, ribonucleotide reductase, or a transcriptional activator.

30           17.     The method of claim 15 in which said drug or drug candidate inhibits the growth of a human tumor.

SUB B1)           18.     A method of rational antitumor drug design comprising: (i) providing a genetically tractable organism harboring an altered gene that is analogous or homologous to a primary tumor defect, (ii) performing a synthetic lethal screen to identify a secondary  
35     target gene, (iii) determining an analogous or homologous secondary target in

5  
SUB(B)  
C64  
mammalian cells, and (iv) using said analogous or homologous secondary target to screen  
for a drug or drug candidate having antitumor activity.

19. The method of claim 18 in which said drug or drug candidate comprises a  
small molecule.

10  
20. The method of claim 17 which further comprises validating the synthetic  
lethality of said analogous or homologous secondary target in a mammalian tumor cell  
relative to a mammalian non-tumor cell.

15  
21. A method of treating a cancer comprising administering to a cancer patient  
an effective amount of an anticancer agent, which anticancer agent interacts with, binds  
to, or inhibits a gene product of a secondary target gene present in a mammalian tumor  
cell.

20  
22. The method of claim 21 in which said secondary target gene is identified  
by performing a synthetic lethal screen.

23. The method of claim 1 in which said primary gene defect includes a defect  
in a gene coding for PIK-related kinase (mec1).

25  
24. The method of claim 1 in which said secondary site mutation is effected  
within a gene selected from the group consisting of RNR1, RNR2, RNR4, CDC8,  
CDC21, SHM2, PRII, CDC17, MBP1, SLM1, SLM2, SLM3, and SLM4.

30  
25. The method of claim 1 in which said primary gene defect includes a defect  
in a gene coding for PIK-related kinase (mec1), and said secondary site mutation is  
effected within a gene selected from the group consisting of RNR1, RNR2, RNR4,  
CDC8, CDC21, SHM2, PRII, CDC17, MBP1, SLM1, SLM2, SLM3, and SLM4.

35  
26. A pharmaceutical composition comprising an effective amount of an agent  
derived from the gene product of a lethal secondary site mutation, the expression of

5 which proves lethal to a cell having at least one primary gene defect, and a pharmaceutically acceptable carrier or diluent, said agent comprising said gene product, active fragments thereof, derivatives or analogs thereof, or small molecule or peptide mimetics thereof.

10 27. The pharmaceutical composition of claim 26, wherein the lethal secondary site mutation is a mutation within a yeast gene selected from the group consisting of cdc9, cdc2, a gene encoding a gene product exhibiting polymerase  $\delta$  exonuclease function, a gene encoding a gene product exhibiting polymerase  $\epsilon$  exonuclease function, a gene encoding a ribonucleotide reductase, mec1, rad53 like gene, cdc53, cdc34, cdc14,  
15 cdc15, a gene encoding NUP170, dbf2, a gene encoding CLN2, rad3, rad9, rad27, cdc8, a gene encoding Mlu1-box binding factor, slm1, a gene encoding MBF, a gene encoding PCNA, a gene encoding replication fork protein, RNR1, RNR2, RNR4, CDC21, SHM2, PRII, CDC17, MBP1, SLM1, SLM2, SLM3, and SLM4, or a human gene analogous or homologous to said yeast gene.

20 28. The pharmaceutical composition of claim 27, wherein the human gene comprises a gene encoding a DNA ligase I, a gene encoding a DNA polymerase, a gene encoding a ribonucleotide reductase, a gene encoding a FEN-1, a gene encoding Cyclin D, a gene encoding Cyclin E, a gene encoding NUP155, or a gene encoding an isozyme.

25 29. The pharmaceutical composition of claim 27, wherein the human gene comprises an AT-related gene.

30 30. A pharmaceutical composition comprising an effective amount of an agent and a pharmaceutically acceptable carrier or diluent, said agent capable of inhibiting either the expression of a synthetic lethal gene or the activity of the gene product of a synthetic lethal gene that is found in a cell having at least one primary gene defect.

35 31. The pharmaceutical composition of claim 30 in which said agent is effective to arrest division, growth, or viability of said cell.

5

32. The pharmaceutical composition of claim 31 in which said agent does not arrest division, growth, or viability of a cell that does not contain said at least one primary gene defect.

10

33. The pharmaceutical composition of claim 30 in which said synthetic lethal gene comprises a yeast gene selected from the group consisting of cdc9, cdc2, a gene encoding a gene product exhibiting polymerase  $\delta$  exonuclease function, a gene encoding a gene product exhibiting polymerase  $\epsilon$  exonuclease function, a gene encoding a ribonucleotide reductase, mec1, rad53 like gene, cdc53, cdc34, cdc14, cdc15, a gene  
15 encoding NUP170, dbf2, a gene encoding CLN2, rad3, rad9, rad27, cdc8, a gene encoding Mlu1-box binding factor, slm1, a gene encoding MBF, a gene encoding PCNA, a gene encoding replication fork protein. RNR1, RNR2, RNR4, CDC21, SHM2, PRII, CDC17, MBP1, SLM1, SLM2, SLM3, and SLM4, or a human gene analogous or homologous to said yeast gene. 35600

20

34. The pharmaceutical composition of claim 33, wherein the human gene comprises a gene encoding a DNA ligase I, a gene encoding a DNA polymerase, a gene encoding a ribonucleotide reductase, a gene encoding a FEN-1, a gene encoding Cyclin D, a gene encoding Cyclin E, a gene encoding NUP155, or a gene encoding an isozyme. 47

25

35. The pharmaceutical composition of claim 33, wherein the human gene comprises an AT-related gene.

30

36. The pharmaceutical composition of claim 30 in which said agent inhibits the activity of ATR.

37. The pharmaceutical composition of Claim 30, wherein said at least one primary gene defect results in an abnormal accumulation of a human G1/S Cyclin.

5           38.    The pharmaceutical composition of claim 37, wherein said abnormal accumulation of a human G1/S Cyclin is due to overexpression of or decrease in the degradation of the G1/S Cyclin.

10           39.    The pharmaceutical composition of claim 37, wherein said human G1/S Cyclin comprises Cyclin D1 or Cyclin E.

15           40.    The pharmaceutical composition of claim 30, wherein said gene product is selected from (or wherein said synthetic lethal gene codes for) a human isozyme of cdc34, a human isozyme of cdc53, a human isozyme of skp1, a human isozyme of cdc14 and NUP155. *LY*

20           41.    The pharmaceutical composition of claim 30, wherein said gene product is ATR or wherein said synthetic lethal gene codes for ATR.

25           42.    A pharmaceutical composition comprising a drug in a pharmaceutically acceptable carrier or diluent, said drug selectively interacts with the expression or biological activity of at least one gene product in a cell population, said cell population contains at least one primary gene defect, wherein exposure of said cell population to said drug arrests or reduce cell division selectively in said cell population.

          43.    The pharmaceutical composition of claim 42 wherein said interaction comprises total arrest, increase or reduction.

30           44.    A method of treating cancer cells having abnormal accumulation of a human G1/S Cyclin which comprises administering a pharmaceutical composition comprising an effective amount of an agent and a pharmaceutically acceptable carrier or diluent, said agent capable of inhibiting either the expression of a synthetic lethal gene or the activity of the gene product of a synthetic lethal gene that is found in a cell having at least one primary gene defect, wherein said gene product is selected from (or wherein

5 said synthetic lethal gene codes for) a human isozyme of cdc34, a human isozyme of cdc53, a human isozyme of skp1, a human isozyme of cdc14 and NUP155.

45. The method of claim 44 wherein said gene product is an ATR or wherein said synthetic lethal gene codes for ATR.

10

46. The method of claim 45 wherein said ATR is an ATR-dk.

15

20

25

30

35